Novartis: EU approves wider use of psoriasis drug Cosentyx
(CercleFinance.com) - Novartis has received approval from European regulators for a Cosentyx label update that includes dosing flexibility in psoriatic arthritis, the Swiss drugmaker said on Friday.
The new label update includes dosing flexibility of up to 300 mg based on clinical response that will provide clinicians with greater choice for their patients, the company said.
The label update also includes 24-week structural data with subcutaneous regimens demonstrating that Cosentyx inhibits progression of joint damage in psoriatic arthritis, it said.
The label update - which is applicable to all European Union and European Economic Area countries - is effective immediately.
To date, the psoriasis drug Cosentyx has been prescribed to over 160,000 patients worldwide, Novartis said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The new label update includes dosing flexibility of up to 300 mg based on clinical response that will provide clinicians with greater choice for their patients, the company said.
The label update also includes 24-week structural data with subcutaneous regimens demonstrating that Cosentyx inhibits progression of joint damage in psoriatic arthritis, it said.
The label update - which is applicable to all European Union and European Economic Area countries - is effective immediately.
To date, the psoriasis drug Cosentyx has been prescribed to over 160,000 patients worldwide, Novartis said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.